HDL

Accellera Systems Initiative Posthumously Honors Phil Moorby with 2023 Technical Excellence Award

Retrieved on: 
星期三, 三月 1, 2023

ELK GROVE, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Accellera Systems Initiative (Accellera) announced today that Phil Moorby, the inventor of the Verilog Hardware Description Language (HDL) who passed away in September 2022, is honored posthumously with the Accellera 2023 Technical Excellence Award.

Key Points: 
  • ELK GROVE, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Accellera Systems Initiative (Accellera) announced today that Phil Moorby, the inventor of the Verilog Hardware Description Language (HDL) who passed away in September 2022, is honored posthumously with the Accellera 2023 Technical Excellence Award.
  • The award was established to recognize the outstanding achievements of an individual and their significant contributions to the development of its standards.
  • He was honored with many awards for his work, including the prestigious Phil Kaufman Award in 2005.
  • “Phil Moorby invented and evolved the Verilog language, which has become the mainstay for the design of devices we all use every day,” stated Martin Barnasconi, Accellera Technical Committee Chair.

Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV

Retrieved on: 
星期三, 二月 22, 2023

Metabolic syndrome is a condition characterized by central adiposity, high levels of fasting blood glucose, high blood levels of triglycerides, low blood levels of high-density lipoprotein (HDL) cholesterol, and hypertension (high blood pressure).

Key Points: 
  • Metabolic syndrome is a condition characterized by central adiposity, high levels of fasting blood glucose, high blood levels of triglycerides, low blood levels of high-density lipoprotein (HDL) cholesterol, and hypertension (high blood pressure).
  • Metabolic syndrome is associated with increased risk of cardiovascular disease, stroke, and type 2 diabetes.
  • “Given the relationship between EVAF and metabolic syndrome, these data appear to suggest that tesamorelin could improve metabolic profiles in individuals with HIV who have central adiposity.”
    Researchers conducted a post-hoc analysis of data from two Phase III trials of tesamorelin in PWHIV with EVAF.
  • However, following 26 weeks of tesamorelin treatment, the prevalence of metabolic syndrome decreased in responders, resulting in a significantly lower prevalence compared to non-responders (30.8% vs. 48.5%; p

Aldec Releases Automated Static Linting and CDC Analysis for Microchip FPGA and SoC FPGA Designs

Retrieved on: 
星期一, 二月 6, 2023

The new release supports automatic conversion of Libero projects into ALINT-PRO’s environment for static linting and clock domain crossing (CDC) analysis of hardware designs in VHDL, Verilog or SystemVerilog.

Key Points: 
  • The new release supports automatic conversion of Libero projects into ALINT-PRO’s environment for static linting and clock domain crossing (CDC) analysis of hardware designs in VHDL, Verilog or SystemVerilog.
  • CDC analysis is critical to designs with multiple asynchronous clocks and helps mitigate non-deterministic issues such as data incoherence as a result of metastability that inevitably appear in today’s large FPGA and SoC FPGA designs.
  • “The use of advanced verification tools such as static linting and CDC analysis can significantly reduce the number of non-trivial bugs escaping into production, save engineering resource and more importantly, increase the reliability of FPGA and SoC FPGA designs,” said Louie De Luna, Director of Marketing at Aldec.
  • “Designers using Libero SoC Design Suite can take advantage of Aldec’s ALINT-PRO to help detect functional errors earlier in the FPGA design cycle.”
    In conjunction with the latest release of ALINT-PRO, Aldec and Microchip will be conducting a webinar that will be held on March 2, 2023 - Linting and CDC Analysis for Microchip FPGA Designs .

HdL Companies Acquires DataMax Revenue Enhancement

Retrieved on: 
星期二, 一月 31, 2023

HdL Companies , a leading provider of revenue enhancement and management solutions for public agencies, is pleased to announce the acquisition of key assets from NC-based DataMax Corporation, a like-minded firm that specializes in revenue identification and recovery.

Key Points: 
  • HdL Companies , a leading provider of revenue enhancement and management solutions for public agencies, is pleased to announce the acquisition of key assets from NC-based DataMax Corporation, a like-minded firm that specializes in revenue identification and recovery.
  • The combination of DataMax with HdL Companies will create tremendous opportunities for our clients and team members.
  • We are delighted and honored to become associated with HdL Companies,” said DataMax CEO, Lisa Venable.
  • As an affiliate of HdL, DataMax will continue to provide and grow their local government solutions to existing and prospective clients.

QuickLogic Drives eFPGA Innovation with New Aurora™ Development Tool Suite

Retrieved on: 
星期二, 二月 7, 2023

SAN JOSE, Calif., Feb. 7, 2023 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK) has released a new version of its Aurora eFPGA development tool suite. The Aurora 2.1 Development Tool Suite is based on a fully open-source implementation for scalability, longevity, and full code transparency. It supports all major HDLs including Verilog, System Verilog, and VHDL.

Key Points: 
  • - Now supports all major Hardware Description Languages (HDL), including Verilog, System Verilog, and VHDL
    SAN JOSE, Calif., Feb. 7, 2023 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK) has released a new version of its Aurora eFPGA development tool suite.
  • The Aurora 2.1 Development Tool Suite is based on a fully open-source implementation for scalability, longevity, and full code transparency.
  • It supports all major HDLs including Verilog, System Verilog, and VHDL.

Add California Prunes to daily meals and snacks to benefit your bones, heart, and digestive health

Retrieved on: 
星期二, 一月 31, 2023

Filled with fibre, vitamins and antioxidants, California prunes are an important functional food to add to your favourite meals and snacks.

Key Points: 
  • Filled with fibre, vitamins and antioxidants, California prunes are an important functional food to add to your favourite meals and snacks.
  • Prunes have a low glycemic index (29), meaning they won’t cause a dramatic spike in blood sugar levels.
  • Dietitian Cara Rosenbloom explains that this beneficial effect is likely due to the combination of the nutrients found in prunes.
  • California Prunes play an important role in digestive health and are well known for their laxative effect.

GL’s Enhanced Packet Capture and Analysis Tool for Monitoring High Speed Ethernet Networks

Retrieved on: 
星期二, 一月 24, 2023

This application provides wirespeed IP traffic filtering and recording up to 160 Gbps direct to disk for offline filtering, extraction, and analysis.

Key Points: 
  • This application provides wirespeed IP traffic filtering and recording up to 160 Gbps direct to disk for offline filtering, extraction, and analysis.
  • “GL’s FastRecorder™ and PacketExtractor™ is the ultimate packet capture and analysis tool for managing large and small-scale networks for lossless capture of high-speed IP traffic.
  • FastRecorder™ and PacketExtractor™ applications work with GL’s network appliance PacketScan™ HD (or Wireshark®) packet analyzers.
  • The extracted chunks/files can be in PCAP, PCAPNG, or HDL (GL’s proprietary) format for analysis.

Despite Inflation Concerns, HdL Companies Reports Continued Growth for California Sales Tax Returns in 3Q2022

Retrieved on: 
星期四, 一月 12, 2023

“As the Federal Reserve Board continued ramping up interest rates in an effort to curb concerns over inflation, consumers continued purchasing a broad array of goods, especially new automobiles,” stated HdL Companies President/CEO Andy Nickerson.

Key Points: 
  • “As the Federal Reserve Board continued ramping up interest rates in an effort to curb concerns over inflation, consumers continued purchasing a broad array of goods, especially new automobiles,” stated HdL Companies President/CEO Andy Nickerson.
  • HdL is the leading provider of revenue enhancement technology and consulting services for local governments.
  • Each quarter, it reports on California’s sales tax receipts and impacts on local jurisdictions.
  • The automobile sector saw growth of 6% with new car dealers experiencing 10% gains compared to 2021.

InsideTracker Adds Apolipoprotein B (ApoB) Testing To Popular "Ultimate Plan"

Retrieved on: 
星期二, 一月 3, 2023

CAMBRIDGE, Mass., Jan. 3, 2023 /PRNewswire/ -- InsideTracker, the leading personal health analysis and data-driven wellness guide that helps people increase their healthspan and live healthier longer, announced today the company's popular Ultimate Plan will now also measure Apolipoprotein B (ApoB)—an essential indicator of heart health.

Key Points: 
  • Apolipoprotein B, commonly known as ApoB, is the main protein found in low-density lipoproteins.
  • However, emerging research indicates that ApoB is an essential indicator of heart health and heart disease risk.
  • By analyzing your body's biomarkers, InsideTracker provides an objective assessment of the current state of your well-being.
  • Integrated within an intuitive mobile app, InsideTracker reveals your personalized path to improving your health and longevity from the inside out.

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Retrieved on: 
星期四, 十一月 17, 2022

In this patient population, the safety of a potential therapy is of paramount importance."

Key Points: 
  • In this patient population, the safety of a potential therapy is of paramount importance."
  • "We are very encouraged by the detailed data reported today demonstrating a positive safety profile and signs of efficacy for our oral insulin program to treat NASH," said Oramed's Chief Executive Officer, Nadav Kidron.
  • As previously announced, the Phase 2 trial enrolled 32 patients (with 30 patients completing) over a treatment period of 12-weeks.
  • ORA-D-N02 is a Phase 2 double-blind, randomized, placebo-controlled, multicenter trial to assess the safety and efficacy of Oramed's oral insulin candidate, ORMD-0801, to reduce liver fat content in T2D patients with NASH.